探讨PCR产物酶联免疫检测法在乳腺癌临床检验中的临床价值  

Analysis of the clinical value of PCR product enzyme-linked immunosorbent assay in breast cancer clinical examination

作　　者：仇化微 QIU Huawei(Department of Laboratory Medicine,Cancer Hospital Affiliated to Harbin Medical University,Harbin,Heilongjiang 150070,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院检验科,黑龙江哈尔滨150070

出　　处：《国际检验医学杂志》2020年第S02期46-48,共3页International Journal of Laboratory Medicine

摘　　要：目的探析在乳腺癌临床检验中应用聚合酶链式反应(PCR)产物酶联免疫法的临床效果与价值。方法此次研究对象为该院2018年11月至2019年11月期间收治的60例乳腺癌患者,均应用PCR产物酶联免疫法对患者进行检测。以手术病理检查结果作为诊断金标准,对比两种检查方式(PCR产物酶联免疫检测法、手术病理检查)的诊断符合率、灵敏度与特异度。结果PCR产物酶联免疫检测法的诊断符合率为95.00%,灵敏度为96.49%,特异度为66.67%。结论在乳腺癌患者临床检验中应用PCR产物酶联免疫检测法,可促进诊断结果准确性的提高,并为患者治疗方案的制定提供参考。Objective To analyze the clinical effect and value of applying PCR product enzyme-linked immunosorbent assay in the clinical examination of breast cancer.Methods The subjects of this study were 60 breast cancer patients treated in our hospital from November 2018 to November 2019.All patients were detected by PCR-based enzyme-linked immunosorbent assay.The results of surgical pathological examination were used as the diagnostic gold standard,and the diagnostic compliance rate,sensitivity,and specificity of the two inspection methods(PCR product ELISA,surgical pathological examination)were compared.Results The diagnostic coincidence rate of the PCR product ELISA was 95.00%,the sensitivity was 96.49%,and the specificity was 66.67%.Conclusion The application of the enzyme-linked immunosorbent assay for PCR products in the clinical examination of breast cancer patients can promote the improvement of the accuracy of diagnosis results and provide a reference for the formulation of patients′treatment plans.

关 键 词：PCR产物酶联免疫检测法 乳腺癌 临床检验 手术病理检查 

分 类 号：R73[医药卫生—肿瘤]